Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 246

1.

A case report of a diabetic woman with very low HDL cholesterol.

Chaychi L, Kinlaw WB, Asztalos BF, Schaefer EJ.

J Clin Lipidol. 2010 Mar-Apr;4(2):133-5. doi: 10.1016/j.jacl.2010.01.003. Epub 2010 Jan 29. No abstract available.

PMID:
21122641
2.

Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.

Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):427-32. doi: 10.1161/ATVBAHA.113.302019. Epub 2013 Nov 27.

3.
4.
5.

Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.

Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA.

Cardiovasc Drugs Ther. 2011 Feb;25(1):47-57. doi: 10.1007/s10557-010-6273-5.

6.

Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia.

Katabami T, Murakami M, Kobayashi S, Matsui T, Ujihara M, Takagi S, Higa M, Ichijo T, Ohta A, Tanaka Y.

J Int Med Res. 2014 Apr;42(2):457-67. doi: 10.1177/0300060513507648. Epub 2014 Mar 4.

PMID:
24595147
7.

Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report.

Lupattelli G, Roscini AR, Siepi D, Mannarino E.

J Clin Pharm Ther. 2010 Oct;35(5):613-5. doi: 10.1111/j.1365-2710.2009.01118.x.

PMID:
20831686
8.

Rosuvastatin and diabetes: when the evidences talk.

Barrios V, Escobar C.

Cardiovasc Hematol Agents Med Chem. 2013 Jun;11(2):115-24. Review.

PMID:
23094943
9.

Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.

Capuzzi DM, Morgan JM, Carey CM, Intenzo C, Tulenko T, Kearney D, Walker K, Cressman MD.

Prev Cardiol. 2004 Fall;7(4):176-81.

10.

Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes.

Vergès B, Florentin E, Baillot-Rudoni S, Petit JM, Brindisi MC, Pais de Barros JP, Lagrost L, Gambert P, Duvillard L.

J Lipid Res. 2009 Jun;50(6):1209-15. doi: 10.1194/jlr.P800040-JLR200. Epub 2009 Jan 22.

12.

The work-up for mixed hyperlipidemia: a case study.

Rehman HU.

J Fam Pract. 2012 Mar;61(3):133-6.

PMID:
22393551
13.

Surprises and reaffirmations in 2008 clinical trials.

Mandell BF.

Cleve Clin J Med. 2009 Jan;76(1):6. doi: 10.3949/ccjm.76a.01001. No abstract available.

14.

Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.

Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA.

Clin Cardiol. 2010 Oct;33(10):609-19. doi: 10.1002/clc.20830.

15.

[Lipid management--treatment goal and strategy].

Koshiyama H.

Nihon Rinsho. 2006 Nov;64(11):2102-6. Review. Japanese.

PMID:
17087303
16.
17.

Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.

Pan J, Shilian P, Ishida B, Wu X, Kane JP, Malloy MJ, Charles MA.

Metabolism. 2011 Feb;60(2):292-7. doi: 10.1016/j.metabol.2010.01.029. Epub 2010 Mar 29.

PMID:
20303127
18.

Diabetic dyslipidemia: extending the target beyond LDL cholesterol.

Nicholls SJ, Lundman P, Tardif JC.

Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S20-4. doi: 10.1097/01.hjr.0000368195.09485.17. Review.

PMID:
20489416
19.

Exaggerated benefits of rosuvastatin compared with other statins.

Qizilbash N.

Pharmacoepidemiol Drug Saf. 2009 May;18(5):425-6. doi: 10.1002/pds.1728. No abstract available.

PMID:
19382149
20.

Retinopathy progression in type 2 diabetes.

Baum SJ.

N Engl J Med. 2010 Nov 25;363(22):2172; author reply 2173-4. doi: 10.1056/NEJMc1009236#SA3. No abstract available.

PMID:
21105808
Items per page

Supplemental Content

Write to the Help Desk